Novartis Eyes Gene Therapy Growth With Vedere Acquisition
Paying $150m Upfront
The Swiss major is paying up to $280m to buy Vedere Bio, which has developed photoreceptor-protein based optogenetic therapies that are delivered to the retina intravitreally to restore vision.
You may also be interested in...
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.
US regulators refused to accept the file for one of Y-mAbs's neuroblasoma drugs – omburtamab – in October but have given the green light to a second one, naxitamab.